Literature DB >> 22156325

Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis.

Yoshifumi Saisho1, Kumiko Tanaka, Takayuki Abe, Akira Shimada, Toshihide Kawai, Hiroshi Itoh.   

Abstract

It has been reported that beta cell function progressively declines in patients with type 2 diabetes. The objective of this study was to assess the effect of obesity on declining beta cell function after diagnosis of type 2 diabetes. We conducted a cross-sectional study of 689 consecutive subjects with type 2 diabetes who were admitted to our hospital from 2000 to 2007. Fasting and postprandial serum C-peptide immunoreactivity (CPR) and urinary CPR levels had been measured during admission. The subjects were stratified according to BMI and time since diagnosis. CPR index was calculated as CPR (ng/mL) / plasma glucose (mg/dL) x 100. All CPR measurements were significantly higher in the 263 obese (BMI ≥25) subjects compared to the 426 lean subjects (BMI <25). There was a significant negative correlation between CPR indices and duration of diabetes, suggesting a progressive decline in beta cell function after diagnosis of type 2 diabetes. However, this decline was more apparent in obese subjects (postprandial CPR index 0.059/year) compared to lean subjects (0.025/year). The significant difference in serum CPR indices between the lean and obese subjects was lost in subjects more than 10 years after diagnosis. In conclusion, our observations suggest that beta cell function shows a greater progressive decline in obese subjects than in lean subjects with type 2 diabetes. Treatment of obesity may be an important strategy to preserve beta cell function in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156325     DOI: 10.1507/endocrj.ej11-0206

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  World J Diabetes       Date:  2015-02-15

2.  Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.

Authors:  Francesca Porcellati; Jay Lin; Paola Lucidi; Geremia B Bolli; Carmine G Fanelli
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 3.  Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review.

Authors:  Jun Inaishi; Yoshifumi Saisho
Journal:  Nutrients       Date:  2020-12-16       Impact factor: 5.717

4.  Factors affecting glycemic control in diabetes mellitus complicated by autoimmune pancreatitis.

Authors:  Nozomi Harai; Akihiro Nishimura; Kimio Matsumura; Yuya Suzuki; Shota Kikuno; Tetsuro Kobayashi; Kaoru Nagasawa; Yasumichi Mori
Journal:  J Diabetes Investig       Date:  2022-04-12       Impact factor: 3.681

Review 5.  Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.

Authors:  Yoshifumi Saisho
Journal:  J Clin Med       Date:  2014-08-14       Impact factor: 4.241

Review 6.  Alogliptin benzoate for management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  Vasc Health Risk Manag       Date:  2015-04-10

Review 7.  Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?

Authors:  Yoshifumi Saisho
Journal:  Int J Mol Sci       Date:  2014-10-13       Impact factor: 5.923

Review 8.  Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes.

Authors:  Yoshifumi Saisho
Journal:  Int J Mol Sci       Date:  2016-05-17       Impact factor: 5.923

9.  Clinical Significance of the Maximum Body Mass Index Before Onset of Type 2 Diabetes for Predicting Beta-Cell Function.

Authors:  Harutoshi Ozawa; Kenji Fukui; Sho Komukai; Yoshiya Hosokawa; Yukari Fujita; Takekazu Kimura; Ayumi Tokunaga; Junji Kozawa; Hiromi Iwahashi; Iichiro Shimomura
Journal:  J Endocr Soc       Date:  2020-03-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.